Cell MedX Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMXC research report →
About the company
Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing, and marketing both therapeutic and non-therapeutic solutions aimed at individuals suffering from conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and various kidney-related ailments. The company's offerings include the eBalance Pro System, designed for clinical application by medical professionals, and the eBalance Home System, intended for personal use to promote general well-being and alleviate pain.
- CEO
- David M. Jeffs
- IPO
- 2013
- HQ
- Carson City, NV, US
Price Chart
- Market Cap
- $126.33M
- P/E
- -8.13
- P/S
- 0.00
- P/B
- -3.91
- EV/EBITDA
- -13.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 60.42%
- ROIC
- 100.35%
- Revenue
- $0 · 0.00%
- Net Income
- $-566,293 · -297.44%
- EPS
- $-0.03 · -782.35%
- Op Income
- $0
- FCF YoY
- 2.95%
- 52W High
- $0.42
- 52W Low
- $0.42
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.75
- Avg Volume
- 0
Get TickerSpark's AI analysis on CMXC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CMXC coverage
Recent articles, reports, and earnings notes.
No research on CMXC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMXC report →Similar companies
Peers in the same neighborhood.